Rune Wilkens1,2, Rikke H Hagemann-Madsen3,4, David A Peters5, Agnete H Nielsen1, Charlotte B Nørager6, Henning Glerup1, Klaus Krogh2. 1. University Research Clinic for Innovative Patient Pathways, Silkeborg Regional Hospital, Silkeborg, Denmark. 2. Department of Hepatology and Gastroenterology, Aarhus University Hospital, Aarhus, Denmark. 3. Department of Clinical Pathology, Lillebaelt Hospital, Vejle, Denmark. 4. Department of Pathology, Aarhus University Hospital, Aarhus, Denmark. 5. Department of Clinical Engineering, Aarhus University Hospital, Aarhus, Denmark. 6. Department of Colorectal Surgery P, Aarhus University Hospital, Aarhus, Denmark.
Abstract
BACKGROUND AND AIMS: Increased small intestinal wall thickness correlates with both inflammatory activity and fibrosis in Crohn's disease [CD]. Assessment of perfusion holds promise as an objective marker distinguishing between the two conditions. Our primary aim was to determine if relative bowel wall perfusion measurements correlate with histopathological scores for inflammation or fibrosis in CD. METHODS: A total of 25 patients were investigated before elective surgery for small intestinal CD. Unenhanced ultrasonography [US] and magnetic resonance enterography [MRE] were applied to describe bowel wall thickness. Perfusion was assessed with contrast-enhanced US [CEUS] and dynamic contrast-enhanced MRE [DCE-MRE]. Histopathology was used as gold standard. RESULTS: Compared with histopathology, the mean wall thickness was 0.4 mm greater on US [range -0.3 to 1.0, p = 0.24] and 1.4 mm greater on MR [0.4 to 2.3, p = 0.006]. No correlation was found between the severity of inflammation or fibrosis on histopathology, and either DCE-MRE [r = -0.13, p = 0.54 for inflammation and r = 0.41, p = 0.05 for fibrosis] or CEUS [r = 0.16, p = 0.45 for inflammation and r = -0.28, p = 0.19 for fibrosis]. Wall thickness assessed with US was correlated with both histological inflammation [r = 0.611, p = 0.0012] and fibrosis [r = 0.399, p = 0.048]. The same was not true for MR [r = 0.41, p = 0.047 for inflammation and r = 0.29, p = 0.16 for fibrosis]. CONCLUSIONS: Bowel wall thickness assessed with US is a valid marker of inflammation in small intestinal CD. However, relative contrast enhancement of US or of MRE cannot distinguish between inflammatory activity and fibrosis.
BACKGROUND AND AIMS: Increased small intestinal wall thickness correlates with both inflammatory activity and fibrosis in Crohn's disease [CD]. Assessment of perfusion holds promise as an objective marker distinguishing between the two conditions. Our primary aim was to determine if relative bowel wall perfusion measurements correlate with histopathological scores for inflammation or fibrosis in CD. METHODS: A total of 25 patients were investigated before elective surgery for small intestinal CD. Unenhanced ultrasonography [US] and magnetic resonance enterography [MRE] were applied to describe bowel wall thickness. Perfusion was assessed with contrast-enhanced US [CEUS] and dynamic contrast-enhanced MRE [DCE-MRE]. Histopathology was used as gold standard. RESULTS: Compared with histopathology, the mean wall thickness was 0.4 mm greater on US [range -0.3 to 1.0, p = 0.24] and 1.4 mm greater on MR [0.4 to 2.3, p = 0.006]. No correlation was found between the severity of inflammation or fibrosis on histopathology, and either DCE-MRE [r = -0.13, p = 0.54 for inflammation and r = 0.41, p = 0.05 for fibrosis] or CEUS [r = 0.16, p = 0.45 for inflammation and r = -0.28, p = 0.19 for fibrosis]. Wall thickness assessed with US was correlated with both histological inflammation [r = 0.611, p = 0.0012] and fibrosis [r = 0.399, p = 0.048]. The same was not true for MR [r = 0.41, p = 0.047 for inflammation and r = 0.29, p = 0.16 for fibrosis]. CONCLUSIONS: Bowel wall thickness assessed with US is a valid marker of inflammation in small intestinal CD. However, relative contrast enhancement of US or of MRE cannot distinguish between inflammatory activity and fibrosis.
Authors: Ilyssa O Gordon; Dominik Bettenworth; Arne Bokemeyer; Amitabh Srivastava; Christophe Rosty; Gert de Hertogh; Marie E Robert; Mark A Valasek; Ren Mao; Satya Kurada; Noam Harpaz; Paula Borralho; Reetesh K Pai; Rish K Pai; Robert Odze; Roger Feakins; Claire E Parker; Tran Nguyen; Vipul Jairath; Mark E Baker; David H Bruining; J G Fletcher; Brian G Feagan; Florian Rieder Journal: Gastroenterology Date: 2019-08-30 Impact factor: 22.682
Authors: Tom A Watson; Philippe Petit; Thomas A Augdal; E Fred Avni; Costanza Bruno; M Beatrice Damasio; Kassa Darge; Damjana Kjucevsek; Stéphanie Franchi-Abella; Donald Ibe; Annemieke Littooij; Luisa Lobo; Hans J Mentzel; Marcelo Napolitano; Aikaterini Ntoulia; Michael Riccabona; Samuel Stafrace; Magdalena Wozniak; Lil-Sofie Ording Müller Journal: Pediatr Radiol Date: 2019-05
Authors: Rune Wilkens; Dong-Hua Liao; Hans Gregersen; Henning Glerup; David A Peters; Charlotte Buchard; Anders Tøttrup; Klaus Krogh Journal: Diagnostics (Basel) Date: 2022-06-02
Authors: Bella Ungar; Zohar Ben-Shatach; Limor Selinger; Alona Malik; Ahmad Albshesh; Shomron Ben-Horin; Rami Eliakim; Uri Kopylov; Dan Carter Journal: United European Gastroenterol J Date: 2019-09-19 Impact factor: 4.623
Authors: Ilyssa O Gordon; Dominik Bettenworth; Arne Bokemeyer; Amitabh Srivastava; Christophe Rosty; Gert de Hertogh; Marie E Robert; Mark A Valasek; Ren Mao; Jiannan Li; Noam Harpaz; Paula Borralho; Reetesh K Pai; Robert Odze; Roger Feakins; Claire E Parker; Leonardo Guizzetti; Tran Nguyen; Lisa M Shackelton; William J Sandborn; Vipul Jairath; Mark Baker; David Bruining; Joel G Fletcher; Brian G Feagan; Rish K Pai; Florian Rieder Journal: Gut Date: 2021-05-05 Impact factor: 23.059
Authors: Ami Gokli; Jonathan R Dillman; Paul D Humphries; Damjana Ključevšek; Hans-Joachim Mentzel; Erika Rubesova; Marcelo S Takahashi; Sudha A Anupindi Journal: Pediatr Radiol Date: 2021-05-12
Authors: Jie Wang; Sinan Lin; Jonathan Mark Brown; David van Wagoner; Claudio Fiocchi; Florian Rieder Journal: Immunol Rev Date: 2021-05-16 Impact factor: 10.983